CD34 and myelodysplastic syndrome: In a study of 27 patients with higher-risk MDS or AML with myelodysplasia-related changes, the investigators examined the predictive value of specific miRNAs, expressed in bone marrow CD34+ cells before and after the administration of azacytidine [83].